A Phase II Clinical Trial of GTB-1550 for the Treatment of Chemotherapy-Refractive B-Cell Malignancies
Latest Information Update: 04 Jun 2019
At a glance
- Drugs DT2219ARL (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Haematological malignancies
- Focus Therapeutic Use
- Sponsors GT Biopharma
- 04 Jun 2019 New trial record